Browsing by Author "Islam, F."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Comparative study between breast conservative surgery and modified radical mastectomy in early stage of breast carcinoma in a tertiary care hospital
    (Medip Academy, 2023-03) Joty, S. M.; Saiyara, N.; Shishir, M. T. A.; Islam, F.; Khan, M. R.; Sarker, A. K.; Ahsan, S. M. M.; Nuh, M. T.
    Background: Breast cancer is the most prevalent cancer in women globally, with two million new cases and more than half a million deaths each year. Surgery is the key component of treating breast cancer and there are two primary types of breast surgery available: breast conservative surgery and modified radical mastectomy. The aim of this study was to compare BCS and MRM in the treatment of early-stage breast carcinoma. Methods: This was a prospective observational study that involved 74 patients and was carried out in the Department of Surgery at Shaheed Suhrawardy Medical College & Hospital and Enam Medical College & Hospital with an 18-months minimum follow-up. The time frame for inclusion was from July 2018 through July 2020. There were two patient groups, 37 patients in Group A who underwent breast conservative surgery and Group B was made up of 37 individuals who had MRM for early-stage breast carcinoma. Results: With a mean age of 47.65 years in the BCS group and 48.19 years in the MRM group, the operative time for BCS was 1.04±0.25 hours, whereas 3.20±0.48 hours for MRM. Statistically significant higher amount of post-operative drainage volume in MRM group compared to BCS group (p value=0.000). With an excellent aesthetic outcome rate in BCS group (p value<0.0001) as well as better quality of life than MRM group. Conclusions: Breast conservative surgery and modified radical mastectomy are both oncologically safe treatments for early-stage breast cancer with multidisciplinary approach. BCS offers less trauma, infection and hospital stay; better aesthetic outcome and quality of life than MRM, making it more deserving of being promoted clinically in the treatment of early-stage breast cancer.
  • No Thumbnail Available
    Item
    Ensuring global health: a comprehensive review of vaccine regulation with a focus on the Indian perspective
    (Medip Academy, 2024-02) Kumar, N.; Darshan, M.; Islam, F.
    The regulation of vaccines is crucial for ensuring public health and safety. A global perspective on vaccine regulation, with focus on the Indian approach in vaccine regulation, was analysed. The historical evolution of vaccine regulation, highlights significant events that shaped regulatory systems. The role of National Regulatory Authorities (NRAs) in ensuring the safety, efficacy, and quality of vaccines is discussed, along with the pivotal role of the WHO through its prequalification program. The stages of the regulatory review process, including pre-licensure review and post-licensure surveillance, are outlined. The Indian perspective is examined, with a focus on the Central Drugs Standard Control Organization (CDSCO) as the primary regulatory authority. The rigorous vaccine approval process, emergency use authorization, vaccine distribution, and administration, as well as post-marketing surveillance, are discussed. The Indian government's participation in international collaborations and emphasis on indigenous vaccine development are highlighted. This comprehensive review highlights the importance of vaccine regulation and the efforts undertaken by the Indian government to ensure the safety, efficacy, and accessibility of vaccines.
  • No Thumbnail Available
    Item
    Monoclonal antibody: a cell specific immunotherapy to treat cancer
    (Medip Academy, 2023-04) Rahman, M. A.; Islam, F.; Hasan, M.; Joya, I. S.; Mithila, M. M.; Islam, M. F.; Rahman, M. R.
    Fundamentally, the therapy technique which is utilized in malignancy immunotherapy, monoclonal antibodies (mAb), is one of them, and it is used extensively as a treatment for the disease. To achieve more successful treatment, novel combination treatments and treatment procedures must be created. The purpose of this study is the improvement of mAb treatment and detail late advance and new limits, particularly in cancer therapy. With various keywords, we searched Google Scholar, PubMed, and Scopus for monoclonal antibody therapy as an alternate form of chemotherapy. The number of patients who received each therapy regimen, and the recovery rate are all displayed in this study, also a comparative study between monotherapy and chemotherapy. The result showed that rituximab had a greater overall response rate than other drugs, at 68%. In the combination treatment group (monotherapy+chemotherapy), 100% of patients had adverse events, compared to 84.2 percent in the monotherapy group. The pharmaceutical industry's fastest-growing medications, monoclonal antibodies are increasingly being examined in Clinical trials as stand-alone treatments or in conjunction with other therapies. It has a promising future since it will provide better tailored therapy and combination therapy for the treatment of cancer.